

PRESS RELEASE

Camurus' CEO Fredrik Tiberg receives The Arthur D. Little Nordic Life Science Award

Lund, Sweden — 19 March 2025 — Camurus (NASDAQ STO: CAMX) today announced that the company's President & CEO Fredrik Tiberg has been named winner of The Arthur D. Little Nordic Life Science Award 2024. The award aims to strengthen the Nordic life science ecosystem by recognizing and celebrating outstanding leadership of exceptional companies that contribute to advancing healthcare, fostering innovation, and improving patient outcomes.

The jury's motivation for awarding Fredrik Tiberg is: "To recognize his steadfast and strategic leadership in transforming Camurus into a leading innovator in long-acting medicines for severe and chronic diseases. His ability to bridge scientific excellence with strategic execution over the past two decades has been instrumental in unlocking Camurus' full potential, creating long-term value for patients as well as shareholders."

Camurus is committed to improving the lives of patients with severe and chronic diseases, such as opioid dependence, by improving access to innovative and potentially life-changing treatments. Under Fredrik Tiberg's leadership, Camurus has evolved from an early-stage research and development company to a profitable, fast-growing patient-centric biopharmaceutical company with operations in Europe, Australia, and the US.

For more information

Fredrik Tiberg, President & CEO

Tel. +46 (0)46 286 46 92

fredrik.tiberg@camurus.com

Fredrik Joabsson, Chief Business Development Officer

Tel. +46 (0)70 776 17 37

ir@camurus.com

About Camurus

Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and [LinkedIn](#).

This information was submitted for publication at 8:00 am CET on 19 March 2025.